BCM
FBRX

Boxer Capital Management’s Forte Biosciences FBRX Stock Holding History

Boxer Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.83M Buy
+274,500
New +$6.51M 0.44% 36

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
FAM
Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Boxer Capital Management's FBRX Position: Q2 2026 in Review

Boxer Capital Management opened a new position in Forte Biosciences (FBRX) in Q2 2026: 274,500 shares worth $5.83M. The stake represents 0.44% of the portfolio and ranks #36 among its holdings.

86 funds tracked by Wall St. Rank hold FBRX as of Q2 2026.

  • Boxer Capital Management held 274,500 shares of Forte Biosciences worth $5.83M as of Q2 2026.
  • Forte Biosciences was a new Boxer Capital Management position in Q2 2026.
  • Forte Biosciences made up 0.44% of Boxer Capital Management's portfolio in Q2 2026, its #36 holding.
  • 86 funds tracked by Wall St. Rank held Forte Biosciences as of Q2 2026.

Based on Boxer Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.